表紙
市場調査レポート

非小細胞肺癌 (NSCLC) 治療薬:市場・企業・R&Dの展望 (2015-2025年)

Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025

発行 Visiongain Ltd 商品コード 342591
出版日 ページ情報 英文 172 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=133.97円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
非小細胞肺癌 (NSCLC) 治療薬:市場・企業・R&Dの展望 (2015-2025年) Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025
出版日: 2015年10月23日 ページ情報: 英文 172 Pages
概要

当レポートでは、世界の非小細胞肺癌 (NSCLC) 治療薬の市場について調査し、NSCLCとその治療法に関する概要、主な上市済み薬剤の作用機序・市場動向・収益予測、R&Dパイプラインの動向および展望、市場成長推進因子・阻害因子の分析、治療区分および主要国別の市場成長予測などをまとめています。

第1章 レポート概要

第2章 イントロダクション:NSCLCとその治療

  • もっとも一般的な癌である肺癌・その多くがNSCLC
  • 3種の主な組織学的分類
  • 遺伝子突然変異と標的療法
  • NSCLCのステージ
  • 治療プロトコル:ステージ別

第3章 主なNSCLC治療薬の展望

  • Alimta (pemetrexed):Eli Lilly
  • Avastin (bevacizumab):Roche
  • Tarceva (erlotinib):Roche
  • Iressa (gefitinib):AstraZeneca
  • Gilotrif (afatinib):Boehringer Ingelheim
  • Xalkori (crizotinib):Pfizer
  • Abraxane (paclitaxel Protein-Bound):Celgene
  • Taxotere (docetaxel):Sanofi
  • Cyramza (ramucirumab):Eli Lilly
  • Gemzar (gemcitabine):Eli Lilly
  • Zykadia (ceritinib):Novartis
  • Opdivo (nivolumab):Bristol-Myers Squibb
    • 作用機序
    • 収益予測
    • 動向、など

第4章 NSCLCのR&Dパイプラインの予測

  • Alecensa (alectinib):Roche
  • Vargatef (nintedanib):Boehringer Ingelheim
  • AZD9291:AstraZeneca
  • Rociletinib (CO-1686):Clovis Oncology
  • Keytruda (pembrolizumab):Merck (MSD)
  • Ganetespib (STA-9090):Synta Pharmaceuticals
  • Halaven (eribulin):エーザイ
  • Necitumumab:Eli Lilly
  • Atezolizumab (MPDL3280A):Roche

第5章 世界のNSCLC市場の予測

  • 世界のNSCLC市場の予測
  • 成長推進因子
    • 高齢化の進行
    • 標的治療のためのバイオマーカーの特定
    • 有力なパイプラインを持つダイナミックで収益性の高い部門
    • 扁平上皮癌の治療という大きなアンメットニーズの充足
  • 成長阻害因子
    • 特許の失効・ジェネリック医薬品による侵食
    • 新薬の薄い効果
    • 医療予算の縮小
  • SWOT分析

第6章 主要治療区分・主要国別の予測

  • 治療区分別の構成:実績・予測
    • 化学療法
    • EGFR・ALK阻害剤
    • VEGF/VEGFR阻害剤
    • 免疫療法
  • 主要国市場
    • 世界市場の地域構成:実績・予測
    • 主要国市場の予測
    • 米国
    • EU5カ国
      • ドイツ
      • フランス
      • イタリア
      • 英国
      • スペイン
    • 日本
    • BRIC諸国
      • 中国
      • ブラジル
      • ロシア
      • インド

第7章 調査インタビュー

  • Novartis

第8章 総論

図法

目次
Product Code: PHA0075

Non-Small Cell Lung Cancer - Now Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities

Are you interested in the future of lung cancer treatments? Our new analysis forecasts drug revenues for non-small cell lung cancer (NSCLC). There you find outlooks for sales growth. You also explore trends, results, R&D and opportunities, seeing commercial prospects.

Visiongain's report gives revenue predictions to 2025 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and revenues those cancer drugs can achieve.

Read on, then, to explore that industry for lung cancer therapies and see what future revenue its expanding pharmaceuticals market could generate.

Predictions and other analysis to benefit your research, assessments, plans and decisions

The future looks promising for pharma companies treating those pulmonary cancers. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2015, what revenues and other progress are possible.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing outlooks. You also gain 83 tables, 49 charts and an interview with Novartis.

Our study's purpose is to help your research, analyses and decisions on non-small cell lung cancer, also benefiting your authority and reputation for commercial insight. Stay ahead.

Although no single report covers everything, the following sections show how our new investigation benefits your work.

image1

image2

Forecasts covering the overall world market and segments for treating that lung cancer

Discover in our new analysis revenue predictions to 2025 for NSCLC submarkets at world level. See what is possible for these four therapeutic classes:

  • Chemotherapies
  • EGFR and ALK inhibitors
  • VEGF and VEGFR agents
  • Immunotherapy.

Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and outlooks.

That way you see how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a rising incidence of those lung cancers, the demand for better treatments will continue to bolster that industry and market. Discover what is possible.

You also find sales forecasts by product, exploring how those agents can succeed.

Predictions of leading products' sales - what is possible for those cancer-treating drugs?

How will individual NSCLC medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of these 11 brands:

  • Alimta (pemetrexed) by Eli Lilly
  • Avastin (bevacizumab) by Roche
  • Tarceva (erlotinib) by Roche
  • Iressa (gefitinib) by AstraZeneca
  • Gilotrif (afatinib) by Boehringer Ingelheim
  • Xalkori (crizotinib) by Pfizer
  • Abraxane (paclitaxel Protein-Bound) by Celgene
  • Taxotere (docetaxel) by Sanofi
  • Cyramza (ramucirumab) by Eli Lilly
  • Zykadia (ceritinib) by Novartis
  • Opdivo (nivolumab) by Bristol-Myers Squibb.

image3

There you see how high sales can go, finding products and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds for treating non-small cell lung cancer. Our work also shows you geographical predictions, by country.

National markets - what outlooks for those anticancer drug revenues?

Advances in the biopharma industry expand the range and use of medicines to treat NSCLC in developed and developing countries. Our work shows you individual revenue forecasts to 2025 for 11 national markets:

  • The United States
  • Japan
  • Germany, France, the United Kingdom, Italy and Spain (EU5 countries)
  • Brazil, Russia, India and China (BRIC group).

That way you assess regions with highest revenues and potential sales growth. Explore outlooks for treating those diseases, including patients' and healthcare providers' needs.

You also examine developments leading to novel and improved NSCLC treatments.

R&D for those anticancer medicines - trends, innovations and progress

In our study you investigate that oncology - research and development on that pulmonary disease. You examine technological advances, exploring clinical trials and what they mean.

There, in particular, you find discussions of nine R&D pipeline candidates for non-small cell lung cancer:

  • Alecensa (alectinib) by Roche
  • Vargatef (nintedanib) by Boehringer Ingelheim
  • AZD9291 by AstraZeneca
  • Rociletinib (CO-1686) by Clovis Oncology
  • Keytruda (pembrolizumab) by Merck (MSD)
  • Ganetespib (STA-9090) by Synta Pharmaceuticals
  • Halaven (eribulin) by Eisai
  • Necitumumab by Eli Lilly
  • Atezolizumab (MPDL3280A) by Roche.

Researchers' investigation of specific genetic mutations has led to the development of targeted therapies that offer greater hope for the treatment of the late-stage disease.

See, then, what is possible. R&D also gains momentum from rising disease prevalence and other forces making treatments for those pulmonary disorders more widely used.

Events and changes affecting companies treating that lung disease

Explore other issues, too, including these forces shaping the industry and market for that lung disorder:

  • Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
  • Treatment protocols by stage and for patient populations - maintenance, second-line and third-line therapies
  • Regulators' views and cost-effectiveness - challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets
  • Recent approval for the NSCLC indication - expanding treatment options
  • Overcoming patent expiries and competition from generic drugs
  • Identification of biomarkers for targeted therapies, advancing treatment protocols.

You also gain SWOT analysis, assessing what drives and restrains that prominent, expanding anticancer drugs market.

See, then, what is possible for leading pharma companies and specialists in biological drugs and related biotechnologies for combating NSCLC.

Leading organisations and overall 2019 market value - what revenues are possible?

Our work predicts the world market for those drugs will reach $8.8bn in 2019. That industry will achieve revenue expansion from 2015 to 2025. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.

That way you assess what organisations hold most potential. For NSCLC therapies you explore drug developers, producers and marketers serving those therapeutic needs.

You also gain an exclusive interview with Novartis. Discover what the future holds for companies in that market, exploring what they say and do, as well as their prospects.

7 ways Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025 helps you

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:

  • Revenues for NSCLC drug therapies to 2025 - assess that overall world market's potential, seeing scope for investments, developments, production and marketing
  • Submarket revenues to 2025 covering 4 therapeutic segments - explore treatment categories, seeing their sales outlooks from 2015
  • Leading products' sales to 2025 - discover predicted revenues of 11 top brands, seeing how well those medicines can compete and succeed
  • National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
  • R&D activities - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinion - examine participants in that rising market, gaining insight to help you stay ahead and benefit your influence
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else, helping you succeed.

Gain predictions for treating NSCLC, getting information to help you stay ahead

With our independent study you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help lung cancer patients.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study. Our investigation shows you data, trends, opportunities and forecasts for that expanding anticancer market. So avoid missing out - please get our new report here now.

Table of Contents

1. Report Overview

  • 1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
  • 1.2 Why You Should Read this Report
  • 1.3 How this Report Delivers
  • 1.4 Main Questions Answered by this Report
  • 1.5 Who is this Report for?
  • 1.6 Research and Analysis Methods
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to NSCLC and its Treatment

  • 2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
  • 2.2 The Three Main Histological Sub-Types of NSCLC
  • 2.3 Genetic Mutations Allow for Targeted Therapies
  • 2.4 Staging of NSCLC
  • 2.5 Treatment Protocols by Stage
    • 2.5.1 Stage 1 or 2
    • 2.5.2 Stage 3
    • 2.5.3 Stage 4: First Line-Therapy
      • 2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
      • 2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
      • 2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
    • 2.5.4 Maintenance Therapy
    • 2.5.5 Second-Line and Third-Line Therapy

3. Leading NSCLC Drugs, 2015-2025

  • 3.1 Alimta (pemetrexed) by Eli Lilly - The Leading NSCLC Therapy
    • 3.1.1 Mechanism of Action
    • 3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
    • 3.1.3 Patent Expiries
    • 3.1.3.1 'Method-Of-Use' Vitamin Dosage Regimen Patent - Alimta's Saviour from Generic Competition?
    • 3.1.4 NICE Rejects Alimta for Maintenance Therapy
    • 3.1.5 Total Alimta Revenues, 2010-2014
    • 3.1.6 Alimta for NSCLC, 2014
    • 3.1.7 Alimta for NSCLC Forecast, 2015-2025
  • 3.2 Avastin (bevacizumab) - Roche's Cancer Behemoth is a Leading Presence in NSCLC
    • 3.2.1 Mechanism of Action
    • 3.2.2 Multiple Approved Indications, but NSCLC was one of the First
    • 3.2.3 Growing Discontent with Avastin in NSCLC - Is it Cost-Effective?
    • 3.2.4 Total Avastin Revenues, 2010-2014
    • 3.2.5 Avastin for NSCLC Forecast, 2015-2025
  • 3.3 Tarceva (erlotinib) by Roche
    • 3.3.1 Mechanism of Action
    • 3.3.2 Three of Four Indications are for NSCLC
    • 3.3.3 NICE Changes Mind on Tarceva - and then Changes it Back Again
    • 3.3.4 Total Tarceva Revenues, 2010-2014
    • 3.3.5 Tarceva for NSCLC Forecast, 2015-2025
  • 3.4 Iressa (gefitinib) by AstraZeneca
    • 3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
    • 3.4.2 Iressa NSCLC Revenues, 2010-2014
    • 3.4.3 Iressa for NSCLC Forecast, 2015-2025
  • 3.5 Gilotrif (afatinib) by Boehringer Ingelheim
    • 3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
    • 3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
    • 3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
  • 3.6 Xalkori (crizotinib) by Pfizer
    • 3.6.1 Mechanism of Action
    • 3.6.2 The First Approved ALK Inhibitor
    • 3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
    • 3.6.4 Xalkori NSCLC Revenues, 2012-2014
    • 3.6.5 Xalkori for NSCLC Forecast, 2015-2025
  • 3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
    • 3.7.1 Mechanism of Action
    • 3.7.2 Relatively Recent Approval for NSCLC Indication
    • 3.7.3 Finally Approved for NSCLC in the EU
    • 3.7.4 Total Abraxane Revenues, 2010-2014
    • 3.7.5 Abraxane for NSCLC Forecast, 2015-2025
  • 3.8 Taxotere (docetaxel) by Sanofi
    • 3.8.1 Mechanism of Action and Approved Indications
    • 3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
    • 3.8.3 Total Taxotere Revenues, 2010-2014
    • 3.8.4 Taxotere for NSCLC Forecast, 2015-2025
  • 3.9 Cyramza (ramucirumab) by Eli Lilly
    • 3.9.1 Mechanism of Action
    • 3.9.2 Many Approvals in Quick Succession
    • 3.9.3 Cyramza for NSCLC Forecast, 2015-2025
  • 3.10 Gemzar (gemcitabine) by Eli Lilly
  • 3.11 Zykadia (ceritinib) by Novartis
    • 3.11.1 Mechanism of Action and Recent Approval
    • 3.11.2 Zykadia for NSCLC Forecast, 2015-2025
  • 3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
    • 3.12.1 Mechanism of Action - Works With the Immune System to Fight Cancers
    • 3.12.2 Swift Approvals through FDA Priority Review Programmes
    • 3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
    • 3.12.4 Opdivo for NSCLC Forecast, 2015-2025

4. NSCLC R&D Pipeline, 2015-2025

  • 4.1 Alecensa (alectinib) by Roche
    • 4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
    • 4.1.2 Roche is Inching Closer Towards the All-Important US Approval
    • 4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
    • 4.1.4 Japanese Revenues and Future Outlook
  • 4.2 Vargatef (nintedanib) by Boehringer Ingelheim
    • 4.2.1 EU Becomes First Region to Approve Vargatef
    • 4.2.2 NICE has a Change of Heart on Vargatef
    • 4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
  • 4.3 AZD9291 by AstraZeneca
    • 4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
    • 4.3.2 Collaboration with Roche to Develop Companion Diagnostic
    • 4.3.3 Positive Preliminary Results Presented at ASCO 2015
    • 4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
  • 4.4 Rociletinib (CO-1686) by Clovis Oncology
    • 4.4.1 In a Race to Approval Against AZD9291
    • 4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
    • 4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
  • 4.5 Keytruda (pembrolizumab) by Merck (MSD)
    • 4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
    • 4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
  • 4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
    • 4.6.1 Ganetespib Mechanism of Action
    • 4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
  • 4.7 Halaven (eribulin) by Eisai
    • 4.7.1 Halaven Mechanism of Action
    • 4.7.2 Clinical Trials Involving Halaven in NSCLC
  • 4.8 Necitumumab by Eli Lilly
    • 4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
    • 4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
    • 4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
  • 4.9 Atezolizumab (MPDL3280A) by Roche
    • 4.9.1 Mechanism of Action
    • 4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
    • 4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC

5. Global NSCLC Market, 2015-2025

  • 5.1 The Global NSCLC Market Forecast, 2015-2025
  • 5.2 What Factors will Drive Growth in the Global NSCLC Market?
  • 5.3 Growing Ageing Population
  • 5.4 The Identification of Biomarkers for Targeted Therapies
  • 5.5 Dynamic and Lucrative Sector with Strong Pipeline
  • 5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
  • 5.7 What Factors will Restrain Growth in the Global NSCLC Market?
  • 5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
  • 5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
  • 5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
  • 5.11 SWOT Analysis of the Global NSCLC Market

6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market

  • 6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
    • 6.1.1 Therapeutic Segments Forecast, 2015-2025
    • 6.1.2 Chemotherapy Segment Forecast, 2015-2025
    • 6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
    • 6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
    • 6.1.5 Immunotherapy Segment Forecast, 2015-2025
  • 6.2 Leading National Markets for NSCLC
    • 6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
    • 6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
    • 6.2.3 US NSCLC Market, 2015-2025
    • 6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
    • 6.2.3.2 US NSCLC Market Forecast, 2015-2025
    • 6.2.4 EU5 NSCLC Market, 2015-2025
    • 6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
    • 6.2.4.2 German NSCLC Market Forecast, 2015-2025
    • 6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
    • 6.2.4.4 French NSCLC Market Forecast, 2015-2025
    • 6.2.4.5 Italian NSCLC Market
    • 6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
    • 6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
    • 6.2.4.8 UK NSCLC Market Forecast, 2015-2025
    • 6.2.4.9 Spanish NSCLC Market
    • 6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
    • 6.2.5 Japanese NSCLC Market
    • 6.2.5.1 Expansion of the Generics Market is a Key Factor
    • 6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
    • 6.2.6 BRIC NSCLC Market, 2015-2025
    • 6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
    • 6.2.6.2 China NSCLC Market Forecast, 2015-2025
    • 6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
    • 6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
    • 6.2.6.5 Russian NSCLC Market: Punches Below its Weight
    • 6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
    • 6.2.6.7 Indian NSCLC Market: Generics are King
    • 6.2.6.8 Indian NSCLC Market Forecast, 2015-2025

7. Research Interview

  • 7.1 Interview with Novartis
    • 7.1.1 On the Need for More than one ALK Inhibitor on the Market
    • 7.1.2 Main Trends and Opportunities for NSCLC
    • 7.1.3 The Present and the Future

8. Conclusions from Our Research and Analysis

  • 8.1 How Will Revenues Change over the Forecast Period?
  • 8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
  • 8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
  • 8.4 Concluding Remarks

List of Tables

  • Table 1.1 Currency Exchange Rates: Average Exchange Rate to USD
  • Table 2.1 Example NSCLC First-Line Therapy Options for the Different Patient Populations
  • Table 3.1 FDA-Approved Indications for Alimta, 2004-2009
  • Table 3.2 Patent Expiries for Alimta, 2015-2022
  • Table 3.3 Total Alimta Revenues ($bn), AGR (%), CAGR (%), 2010-2014
  • Table 3.4 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.5 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.6 FDA-Approved Indications for Avastin, 2004-2014
  • Table 3.7 Total Avastin Revenues ($bn), AGR (%), CAGR (%), 2010-2014
  • Table 3.8 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.9 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.10 FDA-Approved Indications for Tarceva, 2004-2013
  • Table 3.11 Total Tarceva Revenues ($bn), AGR (%), CAGR (%), 2010-2014
  • Table 3.12 Tarceva NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.13 Tarceva for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.14 Total Iressa Revenues ($bn), 2010-2014
  • Table 3.15 Iressa NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.16 Iressa for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.17 Gilotrif NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.18 Gilotrif for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.19 Total Xalkori Revenues ($bn), AGR (%), CAGR (%), 2012-2014
  • Table 3.20 Xalkori NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.21 Xalkori for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.22 FDA-Approved Indications for Abraxane, 2005-2013
  • Table 3.23 Total Abraxane Revenues ($bn), AGR (%), CAGR (%), 2010-2014
  • Table 3.24 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.25 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.26 FDA-Approved Indications for Taxotere, 1999-2006
  • Table 3.27 Total Taxotere Revenues ($bn), AGR (%), CAGR (%), 2010-2014
  • Table 3.28 Taxotere NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.29 Taxotere for NSCLC Forecast: Revenues ($bn), AGR (%),CAGR (%), 2020-2025
  • Table 3.30 FDA-Approved Indications for Cyramza, 2014-2015
  • Table 3.31 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.32 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.33 FDA-Approved Indications for Abraxane, 1996-2006
  • Table 3.34 Zykadia NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.35 Zykadia for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 3.36 Opdivo NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 3.37 Opdivo for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 4.1 Currently Ongoing Clinical Trials Involving Alectinib in NSCLC
  • Table 4.2 Selected Ongoing Clinical Trials Involving Vargatef in NSCLC
  • Table 4.3 Selected Ongoing Clinical Trials Involving AZD9291 in NSCLC
  • Table 4.4 Ongoing Clinical Trials Involving Rociletinib in NSCLC
  • Table 4.5 Selected Ongoing Clinical Trials Involving Keytruda in NSCLC
  • Table 4.6 Ongoing Clinical Trials Involving Ganetespib in NSCLC
  • Table 4.7 Clinical Trials Involving Halaven in NSCLC
  • Table 4.8 Selected Ongoing Clinical Trials Involving Necitumumab in NSCLC
  • Table 4.9 Ongoing Clinical Trials Involving Atezolizumab in NSCLC
  • Table 5.1 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
  • Table 5.2 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
  • Table 6.1 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.2 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.3 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.4 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.6 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.7 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.8 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.9 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.10 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.11 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.12 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.13 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.14 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.15 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.16 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.17 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.18 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.19 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.20 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.21 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.22 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.23 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.24 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.25 Japanese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.26 Japanese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.27 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.28 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.29 Brazilian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.30 Brazilian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.31 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.32 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
  • Table 6.33 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
  • Table 6.34 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025

List of Figures

  • Figure 2.1 Example Adjuvant Chemotherapy Regimens for NSCLC in Stage 1 or Stage 2
  • Figure 2.2 Example Chemotherapy Regimens for Use in Concurrent Chemotherapy / Radiation in Stage 3 NSCLC
  • Figure 2.3 Example Chemotherapy Regimens for use in Stage 4 NSCLC
  • Figure 3.1 Total Alimta Revenues ($bn), 2010-2014
  • Figure 3.2 Alimta for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.3 Total Avastin Revenues ($bn), 2010-2014
  • Figure 3.4 Avastin for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.5 Total Tarceva Revenues ($bn), 2010-2014
  • Figure 3.6 Tarceva for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.7 Total Iressa Revenues ($bn), 2010-2014
  • Figure 3.8 Iressa Revenues Regional Breakdown: Revenues ($bn), Market Share (%), 2014
  • Figure 3.9 Iressa for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.10 Gilotrif for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.11 Total Xalkori Revenues ($bn), 2012-2014
  • Figure 3.12 Xalkori for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.13 Total Abraxane Revenues ($bn), 2010-2014
  • Figure 3.14 Abraxane for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.15 Total Taxotere Revenues ($bn), 2010-2014
  • Figure 3.16 Taxotere for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.17 Cyramza for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.18 Zykadia for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 3.19 Opdivo for NSCLC Forecast: Revenues ($bn), 2015-2025
  • Figure 5.1 Global NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 5.2 SWOT Analysis of Global NSCLC Market, 2015
  • Figure 6.1 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2015
  • Figure 6.2 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2025
  • Figure 6.3 Therapeutic Segments within the NSCLC Market: Revenues ($bn), 2015-2025
  • Figure 6.4 Chemotherapy Segment: Revenues ($bn), 2015-2025
  • Figure 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), 2015-2025
  • Figure 6.6 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), 2015-2025
  • Figure 6.7 Immunotherapy Segment: Revenues ($bn), 2015-2025
  • Figure 6.8 Regional Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2015
  • Figure 6.9 Regional Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2025
  • Figure 6.10 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), 2015-2025
  • Figure 6.11 US NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.12 German NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.13 French NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.14 Italian NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.15 UK NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.16 Spanish NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.17 Japanese NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.18 Chinese NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.19 Brazilian NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.20 Russian NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 6.21 Indian NSCLC Market Forecast: Revenues ($bn), 2015-2025
  • Figure 8.1 Global NSCLC Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2015-2025
  • Figure 8.2 Breakdown by Submarket: Revenues ($bn), 2015-2025
  • Figure 8.3 Leading National Markets: Revenues ($bn), 2014
  • Figure 8.4 Leading National Markets: Revenues ($bn), 2025

Companies Listed

  • Abbott
  • Abraxis
  • Actavis
  • American Cancer Society
  • American Society of Clinical Oncology
  • Amgen
  • Apotex
  • AstraZeneca
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Chiba University Hospital (Japan)
  • Chugai
  • Clovis Oncology
  • Committee for Medicinal Products for Human Use (CHMP)
  • Eisai
  • Eli Lilly
  • EMD Serono
  • European Commission
  • European Medicines Agency (EMA)
  • European Union (EU)
  • German Institute for Quality and Efficiency in Health Care (IQWiG)
  • Hospira
  • Merck (MSD)
  • Merck KGaA
  • Ministry of Health, Labour and Welfare (MHLW, Japan)
  • National Comprehensive Cancer Network (NCCN)
  • Novartis
  • Oanda
  • Oncologic Drugs Advisory Committee (ODAC)
  • Pfizer
  • Qiagen
  • Roche
  • Roche Molecular Systems Inc
  • Sanofi
  • Swiss Re
  • Synta Pharmaceuticals
  • Teva
  • The Court of Appeal (England)
  • The European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • The High Court (England)
  • The National Health Service (NHS, England)
  • The National Institute for Health and Care Excellence (NICE)
  • US Court of Appeals
  • US Food and Drug Administration (FDA)
  • World Health Organization (WHO)
Back to Top